Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts

Osteoporotic Fractures Clinical Trial

— ROBUST  

Official title:

Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts Versus Acellular Bone Graft Substitutes for Augmentation in the Treatment of Proximal Humeral Fractures as Model for Fractures of Osteoporotic Bone - a Prospective Randomized First in Men Proof of Principle Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01532076
• Other study ID #: 348/10
• Status: Terminated
• Phase: Phase 2
• First received: January 5, 2012
• Last updated: September 16, 2014
• Start date: June 2012
• Est. completion date: September 2014

Study information

• Verified date: September 2014
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Federal Office of Public Health
• Study type: Interventional

Clinical Trial Summary

Failure rates of up to 30% are reported after proximal humeral fractures despite angular-stable devices. This may devastate not only the functional outcome but also the independence of elderly patients.

To increase bone mineral density and thereby holding-strength augmentation is an option. Autologous bone-graft, as current gold-standard, though is questionable in osteoporosis since osteoprogenitors are dysfunctional and the harvesting-morbidity considerable. Adipose tissue seems an alternative cell-source even in presence of osteoporosis.

Stromal vascular fraction (SVF) cells isolated from lipoaspirates display osteogenic and vasculogenic potential and can be harvested in high numbers. Expansion associated with costly good-manufacturers-practice facilities is avoidable, so are repeated interventions. These cells have been successfully used to generate osteogenic composite grafts with intrinsic vascularity in preclinical models.

For translation into clinical practice after a 20 patient external pilot a prospective randomized controlled trial with 270 patients is planned. For the trial lipoaspiration precedes open reduction and internal fixation in individuals over 60 years presenting with a proximal humeral fracture after low-energy trauma. Cells are isolated (Cellution®800/CRS) and wrapped around hydroxyapatite microgranules after embedding in a fibrin-gel for augmentation of the typical bone-void. Clinical/radiological follow-up is at 6 and 12 weeks for immediate complications and after 6, 9 and 12 months. Functional assessment is performed after 6 weeks, 6 and 12 months using the Quick-Dash- and Constant-Score.

The primary outcome is a reduction in secondary dislocation by 50% during the first postoperative year. Secondary dislocation is diagnosed on plain radiographs by an independent board certified radiologist specialised in musculoskeletal imaging if one or more of the following criteria are met:

• More than 20° varus collapse of the humeral head fragment in relation to the humeral shaft

• Screw penetration through the humeral head

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: September 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

Presentation with an isolated proximal humeral fracture after a low-energy trauma (e.g. falling from a standing position) and:

• indication for open reduction and internal fixation with a proximal humeral locking plate (PHILOS®, Synthes, Switzerland) after low energy trauma

• displacement of more than 1 cm between fragments and/or

• angulation of 45° or more between the fragments and/or

• dislocation of the greater tuberosity of 5 mm or more and/or

• patient specific factors like high functional demand etc

• age > 50 years

• postmenopausal status (i.e. 12 continuous month without menstruation)

• informed consent in surgery and study participation

Exclusion Criteria:

• Psychiatric disorder severely impairing co-operation (dementia mini mental Status (MMS) <24, schizophrenia, major depression)

• Pathological fractures caused by other conditions

• Fracture-related nerve injury

• Malignancies under current treatment (i.e. chemotherapy, radiotherapy etc.)

• BMI <20 kg/m2

• Known hypersensitivity to one of the graft components

• Participation in a clinical trial within 3 month before enrolment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fractures, Bone
• Humeral Fractures
• Osteoporotic Fractures

Intervention

Procedure:
• Cellularized composite graft augmentation
liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
• Acellular composite graft augmentation
Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite

Locations

Country	Name	City	State
Switzerland	University Hospital Basel	Basel	Basel-Stadt

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Development of secondary dislocation within 12 months postoperative	Secondary dislocation within the first year postoperative on plain radiographs in ap. and Neer projections diagnosed by an independent radiologist specialized in musculoskeletal imaging in case of; more than 20° varus collapse of the humeral head fragment in relation to the humeral shaft; screw penetration through the humeral head	12 months postoperative	No
Secondary	Functional outcome 6 weeks, 6 and 12 months after fixation	Functional outcome 6 weeks, 6 and 12 months after fixation: the functional outcome will be recorded by the Quick Dash Score and the Constant at each follow up visit and compared between the two groups. Additionally, pain at either surgical site will be recorded via the visual analogue scale.	12 months postoperative	No
Secondary	Safety	safety: all adverse reactions will be recorded and analysed to assess the safety of the approach in a typical patient population.	12 months postoperative	Yes
Secondary	bone mineral density	bone mineral density: in case of implant removal (see below) a 100 mm3 bone biopsy will be taken from the grafted area and analysed with MicroCT (micro computed tomography) for bone mineral density.	12 months postoperative	No
Secondary	Histology	histological assessment of qualitative and quantitative bone formation: bone biopsies will - after MicroCT assessment - be decalcified and histologically analysed using standard techniques and image quantification	12 months postoperative	No
Secondary	Dose-response	establishment of a dose response relationship between number of implanted cells an bone quantity in microCT and histologically via image quantification: retrospectively the quantitative measures of bone formation will be correlated to the number of implanted cells and their clonogenicity	12 months postoperative	No